Cantargia: Negative TNBC Survival Data, as Expected - Redeye
Redeye comments on the survival readout in the phase IIb study TRIFOUR, which investigates nadunolimab + chemotherapy in triple-negative breast cancer.
ANNONS
Redeye comments on the survival readout in the phase IIb study TRIFOUR, which investigates nadunolimab + chemotherapy in triple-negative breast cancer.
